Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Stuttgart (IKP)
The Robert Bosch Gesellschaft fuer Medizinische Forschung mbH (RBMF) is the legal umbrella of the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Stuttgart (IKP), which is the largest Clinical Pharmacology Center in Germany (annual budget 8 million €), covering basic clinical/pediatric pharmacology and clinical trial expertise from phase I to phase IV studies. It is part of the academic teaching Robert Bosch Hospital (RBK, 993 beds) and was funded by the Robert Bosch Stiftung, Stuttgart in 1973. IKP has been awarded several international (FP7, Horizon2020) and national grants (around 10 million € in the last 5 years) and is affiliated with the University of Tuebingen.
IKP is headed by Matthias Schwab, MD who is Professor and Chair of Clinical Pharmacology at the University of Tuebingen and in addition director of the Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany. Currently approx. 100 physicians, biologists, pharmacologists, statisticians (holding PhD or MD degrees), PhD-/MD-/master-students, highly qualified technical staff and study-nurses are employed at IKP.
The mission of the joint endeavors of IKP and RBK in Stuttgart is to take clinical pharmacological research from bench to bedside. IKP holds an international reputation in basic and clinical pharmacogenomic (PGx) research to explain interindividual drug response related to genetic, non-genetic and epigenetic factors and to identify novel drug targets on the basis of disease susceptibility. The ultimate goal of IKP is to provide new strategies for optimizing drug therapy based on each patient's determinants of drug efficacy and toxicity.
The research topic of IKP is particularly dedicated to the metabolism and transport of drugs and drug effects (e.g. expression, regulation and function of drug metabolizing enzymes, transporter molecules and regulator like nuclear receptors). In addition initiation and conduct of clinical trials (particularly principle investigator initiated trials, IIT) are major interests at IKP to demonstrate the clinical relevance and clinical utility of PGx biomarkers. Finally IKP covers clinical pharmacology services like the drug information and safety center for outpatient physicians in the state Baden-Württemberg supported by the Kassenärztliche Vereinigung of Baden-Württemberg.
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
Prof. Matthias Schwab, MD
Phone: +49 711 8101 3700